Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions: Sodium Nitrite, Normal Saline; Drug
Lead sponsor: Hope Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Tampa, Florida • Fort Worth, Texas

Conditions: Postpartum Pain, Postpartum Depression, Opioid Consumption
Interventions: Preservative Free Morphine, Saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Biliary Cholangitis (PBC)
Interventions: Elafibranor, Matched 80 mg placebo; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 43
States / cities: Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more

Conditions: HIV Infections
Interventions: VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP placebo, VRC-HIVADV014-00-VP placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Parkinson Disease
Interventions: Memantine, Placebo; Drug · Other
Lead sponsor: Wayne State University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pain, Abuse, Drug, Intoxication; Cannabinoids
Interventions: Cannabis, Dronabinol, Smoked Placebo, Oral Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma, Non-Hodgkin
Interventions: DZD8586, Placebo; Drug
Lead sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Pulmonary Hypertension
Interventions: Frespaciguat, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Lexington, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions: eptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 77
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Congenital Hyperinsulinism
Interventions: dasiglucagon, Placebo; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 7 Days to 364 Days
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Fort Worth, Texas

Conditions: Cancer
Interventions: Insertion of Pressure Equalization (PE) Tubes, Sodium Thiosulfate (STS), Saline (Placebo), Cisplatin; Procedure · Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure
Interventions: Ivabradine, Placebo; Drug
Lead sponsor: Phillip Levy; Other
Eligibility: 19 Years to 89 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Chronic Hypertension
Interventions: TC-5214; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Overland Park, Kansas • Willingboro, New Jersey

Conditions: Hypertension
Interventions: Salt Pills, Placebo Pills; Dietary Supplement
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Tourette Syndrome
Interventions: d-cycloserine, Placebo pill, Behavior Therapy; Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions: Xanamem, Placebo; Drug
Lead sponsor: Actinogen Medical; Industry
Eligibility: 50 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more

Conditions: Dementia With Lewy Bodies
Interventions: Placebo Oral Tablet, Bosutinib Oral Tablet; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 25 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Progressive Keratoconus
Interventions: Test Article A, Test Article B, Placebo, KXL medical device system; Drug · Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Dementia
Interventions: prazosin hydrochloride, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Postoperative Pain
Interventions: Placebo, Drug .5% Ropivacaine, 20 cc of 0.25% ropivacaine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Kidney Transplant; Complications, Vascular Diseases, Diabetes
Interventions: Dapagliflozin 10mg Tab, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Preeclampsia
Interventions: Aspirin, Placebo Oral Tablet, Progesterone; Drug
Lead sponsor: John Uckele; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Trauma, Opioid Use, Spine Fusion
Interventions: Oxycodone, Ketorolac, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine

Age-dependent Effects of Smoked and Oral Delta-9-THC

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy

Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

Vascular Responses to Sympathetic Activation and Altered Shear Rate: The Impact of Hypertension and Sodium Intake

D-cycloserine Augmented Treatment for Youth With Tic Disorders

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)

Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy

Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia

Relieving Acute Pain (RAP) Study: A Pilot Study